Immune-related adverse events for patients with lung cancer-volume II

被引：0
|
作者：
Wang, Yusha [1 ,2 ]
Wang, Xia [3 ]
Zhan, Cheng [4 ]
Frey, Benjamin [5 ]
Gaipl, Udo S. [5 ]
Shi, Hubing [1 ,2 ]
Ma, Xuelei [1 ,2 ]
机构：
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Biotherapy Res, Chengdu, Sichuan, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[5] Dept Radiat Oncol, Univ Klinikum Erlangen, Erlangen, Germany
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
immune-related adverse events (irAEs); immune checkpoint inhibitors (ICIs); Immunotherapy; lung cancer; editorial;
D O I：
10.3389/fonc.2023.1282394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Immune-Related Adverse Events: Pneumonitis
    Zhong, Linda
    Altan, Mehmet
    Shannon, Vickie R.
    Sheshadri, Ajay
    IMMUNOTHERAPY, 3RD EDITION, 2020, 1244 : 255 - 269
  • [42] Management of Immune-Related Adverse Events
    Fujisaka, Yasuhito
    ANNALS OF ONCOLOGY, 2018, 29 : 45 - 45
  • [43] Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Klein, Brittany A.
    Alves, Fabio Abreu
    de Santana Rodrigues Velho, Julia
    Vacharotayangul, Piamkamon
    Hanna, Glenn J.
    LeBoeuf, Nicole R.
    Shazib, Muhammad Ali
    Villa, Alessandro
    Woo, Sook-Bin
    Sroussi, Herve
    Sonis, Stephen
    Treister, Nathaniel S.
    ORAL DISEASES, 2022, 28 (01) : 9 - 22
  • [44] Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
    Lee, David J.
    Lee, Howard J., Jr.
    Farmer, Jocelyn R.
    Reynolds, Kerry L.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (08)
  • [45] Evaluation of immune checkpoint inhibitors rechallenge after immune-related adverse events in patients with cancer
    Tang, X-R.
    Li, R.
    Zhao, F.
    Wen, X.
    Wang, Y-K.
    Lv, R-X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1269 - S1269
  • [46] Underlying host immune dysregulation in cancer patients developing immune-related adverse events.
    Gerber, David E.
    Khan, Shaheen
    Luo, Xin
    Khan, Saad A.
    Fattah, Farjana
    Saltarski, Jessica
    Gloria-McCutchen, Yvonne
    Park, Jason
    Xie, Yang
    Li, Quan
    Wakeland, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer
    Mouri, Atsuto
    Kaira, Kyoichi
    Yamaguchi, Ou
    Shiono, Ayako
    Miura, Yu
    Hashimoto, Kosuke
    Nishihara, Fuyumi
    Murayama, Yoshitake
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 873 - 880
  • [48] Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
    David J. Lee
    Howard J. Lee
    Jocelyn R. Farmer
    Kerry L. Reynolds
    Current Cardiology Reports, 2021, 23
  • [49] Mechanisms and biomarkers of immune-related adverse events in gastric cancer
    Ding, Ping'an
    Liu, Pengpeng
    Meng, Lingjiao
    Zhao, Qun
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [50] Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
    Simonaggio, Audrey
    Michot, Jean Marie
    Voisin, Anne Laure
    Le Pavec, Jerome
    Collins, Michael
    Lallart, Audrey
    Cengizalp, Geoffray
    Vozy, Aurore
    Laparra, Ariane
    Varga, Andrea
    Hollebecque, Antoine
    Champiat, Stephane
    Marabelle, Aurelien
    Massard, Christophe
    Lambotte, Olivier
    JAMA ONCOLOGY, 2019, 5 (09) : 1310 - 1317
12345